Biotechnology Jobs

• Stevenage
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and leads a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and sets the asset strategy within GSK's oncology R&D portfolio.

mRNA · Checkpoint Inhibitors

• Zug, Switzerland
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability across major markets. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology/biomarkers, manufacturing, regulatory, safety, medical affairs and commercial, and serves as asset spokesperson to senior governance boards.

mRNA · Checkpoint Inhibitors

• Stevenage
• Director

Accountable for GSK R&D's enterprise portfolio of external scientific content and data licenses, managing budget, forecasting, cost controls and vendor commercial terms. Acts as senior interface to information providers and connector across scientific, procurement, legal, copyright and technology teams, ensuring copyright-compliant use and positioning content for AI and text-mining exploitation.

Excel · PowerPoint · Word +2

• London
• Director

Provides advanced scientific expertise in safety evaluation and risk management for key oncology assets in clinical development, leading signal detection, benefit-risk assessment and regulatory safety submissions. Represents the Safety Evaluation & Risk Management function on cross-functional clinical matrix and project teams, escalating emerging safety issues to senior governance. Mentors junior staff and partners with Safety Physicians to shape long-term safety strategy.

• Poznan Grunwaldzka
• PLN 525,750 – PLN 876,250 pa
• Director

Provides advanced scientific expertise in safety evaluation and risk management for key oncology assets in clinical development, leading signal detection, benefit-risk assessment and regulatory safety submissions. Represents SERM on cross-functional clinical matrix teams, escalates emerging safety issues to governance bodies and mentors junior staff within a global matrix environment.

• Belgium-Wavre
• €141,000 – €235,000 pa
• Director

Provides advanced scientific expertise in safety evaluation and risk management for key oncology assets in clinical development, leading signal detection, benefit-risk assessment and regulatory safety submissions. Represents SERM on cross-functional clinical matrix teams, escalates emerging safety issues to governance bodies and mentors junior staff within a global matrix.

• Siena, Italy
• €124,500 – €207,500 pa
• Director

Provides advanced scientific expertise in safety evaluation and risk management for key oncology assets in clinical development, leading signal detection, benefit-risk assessment and regulatory safety submissions. Represents SERM on cross-functional clinical matrix teams, escalates emerging safety issues to governance bodies and mentors junior staff within a global matrix environment.

• USA - Pennsylvania - Upper Providence
• Director

Accountable for GSK R&D's enterprise portfolio of external scientific content and data licenses, including budget, forecasting, cost controls and retiring under-used sources. Manages vendor relationships and commercial terms, maintains copyright-compliant governance and user guidance, and works across scientific, procurement, legal, digital and technology teams to make licensed content AI- and text-mining-ready.

Excel · PowerPoint · Word +2

• Waltham, United States
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Sets disease-area strategy, chairs governance forums and scientific advisory boards, and line-manages clinical development leads and medical directors within a global matrix team.

AI/ML

• Stevenage
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and launch. Provides portfolio oversight, chairs governance forums and scientific advisory boards, and line-manages Clinical Development Leads and Medical Directors within a global matrix team.

AI/ML

• London
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development strategy for a hematology oncology portfolio, from first-in-human studies through registrational trials, regulatory approval and initial launch. Provides program oversight at governance forums, co-leads asset development with matrix partners, and line-manages Clinical Development Leads, Medical Directors and Clinical Scientists. Champions novel approaches such as AI/ML, innovative trial designs and real-world data.

AI/ML

• Upper Providence
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, approval and launch. Sets disease-area strategy, chairs governance forums and advisory boards, and line-manages clinical development leads within a global matrix. Distinct for its portfolio-level enterprise scope and hybrid US/UK/Swiss base.

AI/ML

• Baar Onyx
• Hybrid · 2–3 days in office
• Director · manages people

Leads end-to-end clinical development of hematology oncology assets from first-in-human studies through registrational trials, regulatory approval and initial launch. Chairs governance forums, co-leads matrix asset teams and line-manages clinical development leads, medical directors and clinical scientists. Distinct for its portfolio-level scope across early- and late-phase programs and its cross-functional connector role spanning research, translational medicine and commercial strategy.

AI/ML

• Stevenage
• Director

Leads the development and execution of the analytical (QC testing) network strategy across GSK's global supply chain, translating approved strategy into an operational roadmap and securing endorsement from governance forums such as the Supply Chain Review Board. Drives benchmarking, KPI and reporting frameworks, and capability building across GSC Strategy, with focus on large molecules, ADCs and Oligos.

• Durham, United States
• US$148,500 – US$336,875 pa
• Director

Drives the development and execution of the analytical network strategy across GSK's global supply chain, defining QC testing network principles and translating them into an operational roadmap. Partners with GSC Quality, MSAT, R&D and governance forums on NPI and commercial supply decisions, with a focus on large molecules, ADCs and oligonucleotides. Establishes KPIs and reporting to track strategy impact and mitigate network risk.